<DOC>
	<DOCNO>NCT01380743</DOCNO>
	<brief_summary>This study look Drug-Drug Interactions Between AT2220 ( duvoglustat hydrochloride ) alglucosidase alfa ( ERT ) Patients Pompe Disease .</brief_summary>
	<brief_title>Drug-drug Interaction Study</brief_title>
	<detailed_description>This multi-center , international , open-label , two-period , fixed-sequence crossover study evaluate safety pharmacokinetic effect single ascending dos AT2220 GAA administer 1 hour initiation single alglucosidase alfa infusion . During Period 1 subject receive single intravenous infusion alglucosidase alfa . During Period 2 , subject receive one single oral dose AT2220 one hour prior initiation single alglucosidase alfa infusion .</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>Male female , diagnose Pompe disease 18 65 year age , inclusive Subject stable regimen dose alglucosidase alfa least 3 month screening ( stable regimen define currently receive alglucosidase alfa every 2 week stable dose define vary ± 10 % ) Subject estimate creatinine clearance ≥ 50 mL/min Screening ; eGFR estimate use 4parameter MDRD equation : eGFR ( mL/min/1.73 m2 ) = 175 x ( Scr ) 1.154 x ( Age ) 0.203 x ( 0.742 female ) x ( 1.212 AfricanAmerican ) Male female subject childbearing potential agree use medically accept method contraception study 30 day study completion Subject willing able provide write informed consent able comply study procedure Subject document transient ischemic attack , ischemic stroke , unstable angina myocardial infarction within 3 month Screening Subject clinically significant unstable cardiac disease ( e.g. , cardiac disease require active management , symptomatic arrhythmia , unstable angina NYHA class III IV congestive heart failure ) Subject require mechanical ventilation confine wheelchair Subject history allergy sensitivity study drug ( include excipients ) iminosugars ( e.g. , miglustat , miglitol ) Subject pregnant breastfeeding Subject test positive hepatitis B surface antigen hepatitis C antibody Subject receive investigational/experimental drug device within 30 day Screening Subject intercurrent illness condition may preclude subject fulfil protocol requirement suggest investigator potential subject may unacceptable risk participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pompe disease</keyword>
</DOC>